知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.03 秒)

    Mixture of HMOs for treating autoimmune diseases
    41.
    发明授权
    Mixture of HMOs for treating autoimmune diseases 有权

    公开(公告)号：US11554131B2

    公开(公告)日：2023-01-17

    申请号：US17059942

    申请日：2019-05-31

    申请人： Glycom A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Kristine Rothaus Christensen

    IPC分类号： A61K31/702 ,  A61P37/02

    摘要： The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.

    COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION
    43.
    发明申请
    COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION 有权

    公开(公告)号：US20220233562A1

    公开(公告)日：2022-07-28

    申请号：US17723135

    申请日：2022-04-18

    申请人： Glycom A/S

    发明人： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

    IPC分类号： A61K31/702 ,  A61P1/00 ,  A61K31/7016

    摘要： A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6′-sialyllactose (6′-SL), and a mixture of 6′-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6′-SL and LNT that provides a synergistic effect relative to each of the 6′-SL and LNT alone.

    SYNTHETIC COMPOSITION
    44.
    发明申请
    SYNTHETIC COMPOSITION 有权

    公开(公告)号：US20220133759A1

    公开(公告)日：2022-05-05

    申请号：US17577252

    申请日：2022-01-17

    申请人： Glycom A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

    IPC分类号： A61K31/702 ,  A61P25/00 ,  A61P1/00

    摘要： A method of increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract and regulating levels of one or both of tryptophan and serotonin in a non-infant human is disclosed. In some examples, the method is effective for treating migraines. The method includes administering for an initial treatment period an amount of one or more human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), difucosyllactose (DFL), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), where the amount is effective to increase the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract of the non-infant human.